ASCO 2022 on GEOMETRY-N Trial: Neoadjuvant and Adjuvant Capmatinib in Resectable NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification

961 views
June 8, 2022
Comments 0
Login to view comments. Click here to Login